The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The evolving role of T-cell engagers in myeloma: the MagnetisMM-6 and MELT-MM trials
In this interview, Ja Min Byun, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, discusses the evolving role of T-cell engagers in the treatment of multiple myeloma (MM), focusing on the MagnetisMM-6 (NCT05623020) and MELT-MM (NCT06645678) trials investigating the bispecific antibody elranatamab as part of combination regimens. Dr Byun highlights the change to the control arm that has been made for Part 2 of the MagnetisMM-6 trial, which is evaluating elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with transplant-ineligible or transplant-deferred newly diagnosed myeloma. She also introduces the MELT-MM trial, a Phase I/II study evaluating mezigdomide and elranatamab in relapsed/refractory (R/R) disease, which has shown encouraging initial results. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
